Compare Adaptive Biotechnologies Corp (ADPT) vs Amplitude Inc (AMPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amplitude Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Amplitude Inc trades at $8.89 (market cap $1.21B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.8× Amplitude Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Amplitude Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AMPL | |
|---|---|---|
Market Cap | $3.33B | $1.21B |
Sector | Health | Technology |
52-Week High | $22.37 | $13.29 |
52-Week Low | $10.24 | $5.61 |
Enterprise Value | $3.19B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Amplitude (AMPL) trades at $9.16, up 3.62% on the day, with a bullish technical signal from moving averages. Revenue growth is solid at $343M in 2025, but net losses persist at -$89M. Analyst consensus is 66.7% buy with a $9.00 target. Recent news highlights improving fundamentals but also legal investigations.
The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability challenges and legal risks pose headwinds. Investors should weigh the bullish technicals and growth potential against ongoing losses and regulatory scrutiny for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →
